Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?
1998

Improving survival in recurrent medulloblastoma

Sample size: 116 publication Evidence: moderate

Author Information

Author(s): E Bouffet, F Doz, MC DemaiIle, P Tron, H Roche, D Plantaz, A Thyss, JL Stephan, O Lejars, E Sariban, M BucIon, JM Zucker, M Brunat-Mentigny, JL Bernard, JC Gentet

Primary Institution: Centre Leon Berard, Lyon, France

Hypothesis

The study aims to determine the factors influencing the length of survival in children with recurrent medulloblastoma.

Conclusion

The length of survival in recurrent medulloblastoma is primarily related to specific patterns of relapse and the response to salvage therapy.

Supporting Evidence

  • Forty-six out of 116 patients had progressive or recurrent disease.
  • The median survival time after progression was 5 months.
  • Seventeen patients had asymptomatic relapses detected by the surveillance protocol.
  • Patients with isolated relapses had a significantly longer survival than those with combined relapses.
  • Patients responding to salvage therapy had a significantly better survival than non-responders.

Takeaway

This study looked at children with recurring brain tumors and found that how and when the tumors come back affects how long kids live after that.

Methodology

The study analyzed patterns of recurrences in three consecutive protocols and included a uniform surveillance program with repeated lumbar punctures and imaging scans.

Limitations

The study is retrospective and involved patients treated in a heterogeneous way.

Participant Demographics

Patients were aged less than 20 years, with a mix of high-risk and low-risk classifications based on disease extent.

Statistical Information

P-Value

p=0.00004

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication